JCI Impact Factor

JCI's current impact factor is 13.6 for the 2024 reporting year. The metric is useful, but the decision should be based on trend direction, acceptance dynamics, editorial behavior, and how your manuscript profile matches what editors actually advance.

Data sourced from our analysis of 20,449 journals in the Clarivate JCR 2024 database.

Source: Clarivate Journal Citation Reports (JCR), 2025 edition.

JCI's drop from 19.5 (2021) to 13.6 (2024) follows the COVID normalization pattern seen across translational and clinical journals. JCI's pre-pandemic level was around 13-14, so the current 13.6 is slightly below historical levels but reflects ongoing normalization rather than any change in editorial standards.

What has not changed is JCI's reputation for rigorous peer review and meaningful feedback. Among translational journals in the 10-15 IF range, JCI is still widely treated as a serious editorial venue rather than a metric-first target.

Scopus-based metrics offer a complementary lens to the JCR impact factor. CiteScore uses a four-year citation window instead of two, while SJR weights citations by the prestige of the citing journal. For a translational journal like JCI, these metrics help confirm whether the journal's standing holds up beyond the JCR system.

JCI's SJR of 4.721 confirms that it isn't just well-cited, it's cited by other high-prestige journals, which matters for translational work that bridges basic science and clinical medicine. The h-index of 558 reflects decades of durable, heavily cited translational research.

JCI strongly favors studies that connect molecular mechanism to patient disease biology. Mouse only narratives are often declined unless human tissue, clinical cohorts, or convincing translational linkage is present. Editors want a clear bench to bedside arc, not only mechanistic elegance.

JCI editors require explicit bridging between mechanism and human disease. Mouse-only studies without human samples, patient-derived cells, or at minimum a strong clinical correlation rarely advance. The review criteria explicitly push on clinical significance early. This means papers with strong mouse mechanism but minimal human relevance are often better matched to Immunity, JEM, or another specialty journal.

One operational detail many authors miss is that JCI is known for unusually detailed reviewer feedback even on rejected papers. That does not make it a journal to use casually as a test run, but it does help explain why strong labs still keep it on the shortlist even when the impact factor alone does not look dramatically higher than other options.

JCI is selective but still more accessible than the most extreme flagship-journal lanes. Papers that combine mechanistic depth, strong statistics, and at least one credible human anchor perform best. The sister journal JCI Insight remains a practical fallback for solid but slightly narrower studies.

The main filter is the bench-to-bedside requirement. Papers that do not connect mechanism to human disease are consistently stopped. Once that bar is cleared, the review process focuses on mechanistic rigor and dataset completeness.

Desk rejections often arrive quickly. Peer review decisions are usually measured in weeks, not months. JCI reviewers are known for writing thorough, constructive feedback even on rejections, which is one reason the journal still carries outsized influence relative to impact factor alone.

JCI Insight (IF ~6.1) is worth having as a deliberate strategy, not just a backup. Some teams deliberately publish a first paper in JCI Insight, build on reviewer feedback, then target JCI for a follow-up study. The sister journals share editorial standards and reviewer networks, so the progression is intentional.

JCI rejects roughly 85% of submissions at triage. The editorial team is specific about what they're looking for, and understanding the failure modes can help you self-filter.

Common desk rejection triggers at JCI:

• Mouse-only mechanistic studies without human relevance. This is JCI's most consistent rejection pattern. Papers that present elegant mouse mechanism without human samples, patient-derived material, or an explicit clinical correlation are regularly declined. One well-powered human dataset changes the equation substantially.

• Weak clinical translation statement. Papers that bury the disease relevance in the discussion rather than leading with it at triage. JCI editors want to see the bench-to-bedside connection in the abstract, not just the methods.

• Mechanism without disease specificity. Papers about basic cell biology that aren't connected to a specific disease or clinical condition face harder triage. Even strong mechanistic work needs an explicit disease hook.

• Confirmatory studies without new mechanistic depth. Studies that replicate a known finding in a new cell type, animal model, or patient cohort without adding mechanistic insight are usually declined. JCI values mechanistic novelty, not just additional validation.

• Overpromised clinical relevance. The editorial team is experienced. Papers that assert clinical significance through speculation rather than data, or that overstate translational implications, are often caught and declined at triage.

In our pre-submission review work with manuscripts targeting JCI, three patterns generate the most consistent desk-rejection outcomes. JCI accepts 8-10% of submissions with a desk rejection rate of approximately 50-60%, handled by editors who are active physician-scientists from the American Society for Clinical Investigation.

Mouse-only mechanism without human disease connection. JCI's scope requires papers to advance understanding of the pathogenesis, diagnosis, or treatment of human disease. In practice, editors return manuscripts where the entire experimental evidence derives from mouse models or cell lines without any human tissue validation, patient sample analysis, or clinical biomarker data. This is the most consistently documented pattern in JCI desk rejections: excellent mechanistic work in animal models submitted without the human disease connection that the journal's identity requires. The bar is not a clinical trial. It is a demonstration that the mechanism identified in the model is present or relevant in human disease, through patient samples, human tissue, or validated clinical biomarkers.

Basic science excellence without explicit translational framing. JCI is published by the American Society for Clinical Investigation, a society of physician-scientists, and the editorial culture reflects that identity. Papers that would be considered high-impact at a basic science journal but whose connection to human disease pathophysiology requires multiple inferential leaps routinely fail desk review at JCI. Editors want the translational connection made explicit in the abstract: what disease, what patient population, and what does this mechanism mean for understanding or treating that condition? Leaving those connections implicit for a specialist reader to infer is insufficient for the journal's standard.

Single-model validation without orthogonal mechanistic evidence. JCI reviewers consistently expect mechanistic studies to be supported by orthogonal approaches: genetic knockout data supported by pharmacological intervention or rescue, in vivo findings supported by in vitro mechanism, or human sample findings supported by functional validation. Papers with a single mechanistic validation approach, even in human-relevant models, frequently receive desk rejections noting insufficient rigor. This reflects the ASCI physician-scientist community's expectation of experimental completeness rather than any unusual methodological standard.

A JCI translational bridge check can assess whether the human disease connection is explicit and whether the mechanistic evidence package meets JCI's multi-approach standard.

JCI is published by the American Society for Clinical Investigation (ASCI) and offers a hybrid open access model.

Standard publication (subscription track): No APC. Standard submission and publication with no author charges for qualifying manuscripts. JCI is one of the few high-impact journals in its tier that doesn't charge page fees.

Open access: Authors can pay $3,000 for immediate gold open access under a Creative Commons license. This satisfies most funder mandates.

JCI Insight (the sister open-access journal, IF ~6.1) charges an APC of approximately $2,500. JCI Insight is fully open access and doesn't have a subscription track.

The absence of standard page charges at JCI is notable. Cell Press journals charge $1,000-$1,500 even on accepted papers, and Nature Portfolio charges $11,690 for gold OA. JCI's cost structure is significantly more author-friendly, which is part of why it maintains strong submission volume despite a high bar.

If your manuscript bridges mechanism and human disease with at least one convincing human data layer, submit to JCI before chasing higher IF brands that may desk reject on scope shorthand. This is not a journal to test incomplete narratives. Submit when the manuscript is already in target shape, not when you hope reviewer feedback will create the shape for you.

If you are aiming at this tier and want to reduce desk rejection risk, a JCI translational framing check confirms whether the bench-to-bedside bridge is explicit enough before you submit.

JCI impact factor is 13.6 in 2024.

JCI looks for mechanistic rigor tied directly to human disease relevance, ideally with human data or clear translational grounding.

JCI Insight is the sister journal with a slightly lower selectivity bar and strong fit for solid translational studies.

Yes. It's one of the most respected venues for mechanistic studies that directly connect to human disease.

The 11.4-year cited half-life is JCI's hidden strength. It means JCI papers continue accumulating citations for over a decade, longer than Nature Medicine (6.3 years). If your paper establishes a disease mechanism that other researchers will build on for years, JCI gives it the longest citation runway in translational medicine.

JCI has a distinctive editorial identity focused on disease mechanism:

1. Disease relevance from the first paragraph. JCI doesn't publish basic biology that might someday be relevant. Reviewers expect the disease connection to be explicit and direct from the outset.
2. Human data alongside animal models. Papers with only mouse data face pushback. Reviewers want at least correlative human evidence (patient samples, clinical cohort data, or genetic association data).
3. Therapeutic implication. Not "this could lead to treatments" but "here's the specific therapeutic angle." JCI papers that identify a druggable target or a diagnostic marker are favored.
4. Mechanistic depth. Like Cell Press, JCI wants complete mechanisms. But the mechanism must explain a disease process, not just a biological one.
5. Reproducibility evidence. JCI has been at the forefront of reproducibility standards. Reviewers expect independent validation and transparent reporting of negative results within experiments.

A JCI disease-mechanism framing check is especially useful here because the translational bridge is hard to calibrate. Strong basic science papers get desk-rejected when the human disease connection isn't clear enough.